We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




New Inverted Microscope Designed to Readily Adapt to Changing Research Demands

By LabMedica International staff writers
Posted on 16 Sep 2014
A new inverted microscope for biotech and other life science laboratories was designed to readily accommodate modifications and upgrades to allow it to keep current with changing research demands and interests.

Modularity is the key concept defining the new Leica Microsystems (Wetzlar, Germany) DMi8 inverted microscope, and the core of this concept is the unique illumination port, the "Infinity Port." This port facilitates the integration of additional light sources and laser systems for advanced applications.

To augment the Infinity Port, the Leica DMi8 boasts an innovative closed-loop focus system accurate to 20 nm over a 12 mm travel range, which enables researchers to scan large specimens with high precision.

Modules available for use with the DMi8 allow the user to take advantage of the full range of contrast methods from brightfield, integrated modulation contrast, phase contrast to darkfield, differential interference contrast, and fluorescence. More...


Use of different analysis channels for different fluorescence stains allows the user to analyze several aspects of a sample at the same time. An individual workflow can be assigned to each analysis channel. For example a binary reference mask can be applied to obtain object specific data, such as counting the number of spots in each nucleus. Alternatively, multiple analysis channels can be applied to the same image. Healthy cells can be counted on a stained color image in one analysis channel while a second analysis channel is used to count abnormal cells.

"The Leica DMi8 is an open and freely configurable inverted research microscope which meets the current and future needs of life scientists in a single platform," said Bernard Kleine, product manager at Leica Microsystems. "Universality and individuality have been the heart of our development work. With the Leica DMi8 we serve customer needs ranging from plain microscopy to advanced research applications, and pay heed to the fact that tasks and applications in research change. The Leica DMi8 combines the versatility of an open platform with the user-friendliness of a system solution."

Related Links:

Leica Microsystems



Gold Member
Hematology Analyzer
Medonic M32B
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Pipette
Accumax Smart Series
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Original illustration showing how exposure-linked mutation patterns may influence tumor immune visibility (Photo courtesy of Máté Manczinger, HUN-REN Szeged BRC)

Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response

Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more

Industry

view channel
Image: The partnership with LLS expands access to Lucent’s non-invasive blood-based biomarker tests for early detection of cognitive diseases (photo courtesy of Adobe Stock)

New Partnership Brings Alzheimer’s Blood Biomarker Test to Community Screening Network

Lucent Diagnostics, a brand of Quanterix Corporation, has partnered with Life Line Screening (LLS) to offer Lucent’s non‑invasive, blood‑based biomarker test across the United States. Programs are... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.